skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent

Review

(1980) Views  (494) Full article downloads

Authors: Peter Reimer, Rolf Vosshenrich

Published Date August 2010 Volume 2010:4 Pages 199 - 212
DOI: http://dx.doi.org/10.2147/BTT.S6479

Peter Reimer1, Rolf Vosshenrich2
1Department of Radiology, Klinikum Karlsruhe, Karlsruhe, Germany; 2Radiologen-Gemeinschaftspraxis, MRT im Friederikenstift, Hannover, Germany

Abstract: The value of cross-sectional liver imaging is evaluated by the accuracy, sensitivity, and specificity of the specific imaging technique. Magnetic resonance imaging (MRI) has become a key technique for the characterization and detection of focal and diffuse liver disease. More recently, gadoxetic acid, the hepatocyte-specific MR contrast agent, was clinically approved and introduced in many countries. Gadoxetic acid may be considered a “molecular imaging” probe because the compound is actively taken into hepatocytes via the ATP-dependent organic anion transport system in the plasma membrane for the hepatic uptake. The transport of gadoxetic acid from the cytoplasm to the bile is mainly determined by the capacity of the transport protein glutathione-S-transferase. Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases. Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor–liver contrast when used for gadoxetic acid-enhanced MRI. The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

Keywords: hepatocytes, tumor, gadoxetic acid, liver lesions






Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review
Safety of etanercept in elderly subjects with rheumatoid arthritis
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
Palliative treatment of malignant ascites: profile of catumaxomab
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
New and emerging treatment approaches to lupus
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed